ATE377082T1 - Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damit - Google Patents
Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damitInfo
- Publication number
- ATE377082T1 ATE377082T1 AT99922950T AT99922950T ATE377082T1 AT E377082 T1 ATE377082 T1 AT E377082T1 AT 99922950 T AT99922950 T AT 99922950T AT 99922950 T AT99922950 T AT 99922950T AT E377082 T1 ATE377082 T1 AT E377082T1
- Authority
- AT
- Austria
- Prior art keywords
- connections
- bonded
- methods
- lipidic microparticles
- designing protein
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/076,618 US6210707B1 (en) | 1996-11-12 | 1998-05-12 | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE377082T1 true ATE377082T1 (de) | 2007-11-15 |
Family
ID=22133179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99922950T ATE377082T1 (de) | 1998-05-12 | 1999-05-11 | Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damit |
Country Status (9)
Country | Link |
---|---|
US (5) | US6210707B1 (de) |
EP (2) | EP1078079B1 (de) |
JP (2) | JP4427186B2 (de) |
AT (1) | ATE377082T1 (de) |
AU (1) | AU770111B2 (de) |
CA (1) | CA2330741C (de) |
DE (1) | DE69937450T2 (de) |
ES (1) | ES2296391T3 (de) |
WO (1) | WO1999058694A1 (de) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US20020182258A1 (en) * | 1997-01-22 | 2002-12-05 | Zycos Inc., A Delaware Corporation | Microparticles for delivery of nucleic acid |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
JP2002520038A (ja) * | 1998-07-20 | 2002-07-09 | アイネックス ファーマシューティカルズ コーポレイション | リポソームカプセル化核酸複合体 |
US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
US9034329B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
ES2278597T3 (es) * | 1999-02-22 | 2007-08-16 | Georgetown University | Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administracion sistematica de genes. |
US9034330B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
US6541022B1 (en) * | 1999-03-19 | 2003-04-01 | The Regents Of The University Of Michigan | Mineral and cellular patterning on biomaterial surfaces |
US7713739B1 (en) | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
DE60130741T2 (de) * | 2000-03-02 | 2008-07-03 | Mitsubishi Pharma Corp. | GPib-GEBUNDENES KONSTRUKT UND VERWENDUNGEN DAVON |
WO2001072280A2 (en) * | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for gene therapy |
US7189705B2 (en) * | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
AU2001258659A1 (en) * | 2000-05-30 | 2001-12-11 | Ich Productions Limited | Improved methods of transfection |
US20040142475A1 (en) * | 2000-06-02 | 2004-07-22 | Barman Shikha P. | Delivery systems for bioactive agents |
WO2002004483A1 (en) * | 2000-07-07 | 2002-01-17 | Samokhin Gennady P | Biologically active protein conjugates formed by first protecting active site |
KR100396983B1 (ko) * | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US7090994B2 (en) * | 2001-03-07 | 2006-08-15 | Xenogen Corporation | Methods of screening for introduction of DNA into a target cell |
AU2002256398A2 (en) * | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
WO2002098445A1 (en) * | 2001-05-30 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Protein preparation |
US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
JP2005508306A (ja) * | 2001-07-23 | 2005-03-31 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 哺乳類における遺伝子発現のRNAiによる阻害に関する方法および組成物 |
WO2003038103A1 (en) * | 2001-10-29 | 2003-05-08 | Atso Raasmaja | Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers |
JP4632664B2 (ja) | 2002-02-13 | 2011-02-16 | デューク ユニバーシティ | 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節 |
NZ518163A (en) * | 2002-04-05 | 2005-04-29 | Kiwi Ingenuity Ltd | Embryo modified with a glycolipid to enhance implantation into the endometrium |
AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
WO2004002453A1 (en) | 2002-06-28 | 2004-01-08 | Protiva Biotherapeutics Ltd. | Method and apparatus for producing liposomes |
BR0316871A (pt) * | 2002-12-20 | 2005-10-18 | Botulinum Toxin Res Ass Inc | Composições farmacêuticas aperfeiçoadas de toxina botulìnica |
US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
ATE444984T1 (de) * | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
TW201424770A (zh) | 2003-02-14 | 2014-07-01 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
MXPA05010499A (es) | 2003-03-31 | 2006-05-25 | Johnson & Johnson | Particulas lipidicas que tienen un revestimiento lipidico asimetrico y metodo de preparacion de las mismas. |
US20050112065A1 (en) | 2003-07-09 | 2005-05-26 | Drummond Daryl C. | Remote detection of substance delivery to cells |
WO2005007196A2 (en) | 2003-07-16 | 2005-01-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US20050053590A1 (en) * | 2003-09-05 | 2005-03-10 | The Texas A&M University System | Endothelium-targeting nanoparticle for reversing endothelial dysfunction |
JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
WO2005037858A2 (en) * | 2003-10-16 | 2005-04-28 | University Of Massachusetts | Template-directed assembly of receptor signaling complexes |
US7208174B2 (en) * | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
KR101462819B1 (ko) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
CN1980638B (zh) * | 2004-07-07 | 2011-10-12 | 国立血清研究所 | 用糖脂稳定基于脂质的佐剂制剂的组合物和方法 |
CA2606270A1 (en) * | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
MX2007013200A (es) * | 2005-04-22 | 2008-03-24 | Johnson & Johnson | Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2. |
US20070021594A1 (en) * | 2005-07-25 | 2007-01-25 | Marian Kruszynski | Ligand-binding reagents for quenching and improved purification of lipidated proteins |
WO2007041190A2 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
EP1940444A4 (de) * | 2005-10-20 | 2010-02-10 | Centocor Ortho Biotech Inc | Verfahren zur herstellung von gezielten immunoliposomen |
WO2007080902A1 (ja) * | 2006-01-11 | 2007-07-19 | Kyowa Hakko Kogyo Co., Ltd. | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 |
DE102006011507A1 (de) | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US20070264322A1 (en) * | 2006-05-10 | 2007-11-15 | Huang Ken S | Method for making liposomes conjugated with temperature-sensitive ligands |
EP2049679A4 (de) * | 2006-06-28 | 2010-02-24 | P A Technologies Llc | Verfahren und materialien zur in-vitro-analyse und/oder -verwendung von membranenassoziierten proteinen, teilen davon oder varianten davon |
US20080213349A1 (en) * | 2006-09-11 | 2008-09-04 | Deepak Ramesh Thakker | Liposome Complexes Containing Pharmaceutical Agents and Methods |
EP2068886B1 (de) | 2006-10-03 | 2013-09-18 | Tekmira Pharmaceuticals Corporation | Lipidhaltige formulierungen |
US20090163698A1 (en) * | 2007-05-11 | 2009-06-25 | John Joseph Grigsby | Method for Preparing Antibody Conjugates |
EP2175835B1 (de) * | 2007-07-09 | 2016-04-20 | Georgetown University | Verfahren zur erzeugung einer immunantwort mit durch kationischem liposom vermittelter nukleinsäure-abgabe |
US20100239504A1 (en) * | 2007-07-17 | 2010-09-23 | The General Hospital Corporation | Imaging nucleic acid binding proteins |
EP2177230A4 (de) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | Immunoliposom als induktor von apoptose in todesdomäne-enthaltenden rezeptor exprimierende zelle |
US8709472B1 (en) * | 2007-11-13 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Bioactive agent-loaded heart-targeting nanoparticles |
WO2009067375A1 (en) * | 2007-11-21 | 2009-05-28 | Medical College Of Georgia Research Institute, Inc. | Selective expansion of regulatory t cells |
WO2009127060A1 (en) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
KR20110031168A (ko) * | 2008-06-19 | 2011-03-24 | 니뽄 신야쿠 가부시키가이샤 | 약물 담체 |
WO2009158678A1 (en) | 2008-06-27 | 2009-12-30 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use therefor |
WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
WO2011069528A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
WO2011119881A1 (en) | 2010-03-24 | 2011-09-29 | Northeastern University | Multi-compartmental macrophage delivery |
JP2013522653A (ja) | 2010-03-24 | 2013-06-13 | ノースイースタン ユニヴァーシティ | 早期癌病巣のための多重モード診断技術 |
EP2382994A1 (de) * | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Durch Liganden gezielrichtete Nanokapseln zur Verabreichung von RNAi und anderen Wirkstoffen |
RU2012151823A (ru) | 2010-05-04 | 2014-06-10 | Мерримак Фармасьютикалз, Инк. | Антитела против рецептора эпидермального фактора роста (egfr) и их применение |
WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
CA2820245A1 (en) | 2010-12-06 | 2012-06-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents |
CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
WO2013036827A2 (en) * | 2011-09-08 | 2013-03-14 | The Regents Of The University Of California | Fungal-specific metalloproteases and uses thereof |
US9238865B2 (en) | 2012-02-06 | 2016-01-19 | Asm Ip Holding B.V. | Multiple vapor sources for vapor deposition |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
IN2014DN09050A (de) * | 2012-04-23 | 2015-05-22 | Childrens Medical Ct Corp | |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
CA2892859A1 (en) | 2012-12-03 | 2014-06-12 | Merrimack Pharmaceuticals, Inc. | Combination therapy for treating her2-positive cancers |
US20140363493A1 (en) * | 2013-06-10 | 2014-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016022723A1 (en) | 2014-08-05 | 2016-02-11 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
EP3303585A4 (de) | 2015-06-03 | 2018-10-31 | Board of Regents of the University of Nebraska | Dna-editierung mit verwendung von einzelstrang-dna |
ES2848118T3 (es) | 2015-08-20 | 2021-08-05 | Ipsen Biopharm Ltd | Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer |
PT3337478T (pt) | 2015-08-21 | 2020-10-19 | Ipsen Biopharm Ltd | Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático |
KR20180063255A (ko) | 2015-10-16 | 2018-06-11 | 입센 바이오팜 리미티드 | 캄프토테신 제약 조성물의 안정화 |
US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
US20190070113A1 (en) | 2016-03-16 | 2019-03-07 | Merrimack Pharmaceuticals, Inc. | Treating Ephrin Receptor A2 (Epha2) Positive Cancer with Targeted Docetaxel-Generating Nano-Liposome Compositions |
BR112018068000A2 (pt) | 2016-03-16 | 2019-02-05 | Merrimack Pharmaceuticals Inc | composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2) |
WO2018031771A1 (en) | 2016-08-11 | 2018-02-15 | University Of Iowa Research Foundation | CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA |
SG11201903615WA (en) | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
WO2019161263A1 (en) * | 2018-02-16 | 2019-08-22 | Ohio State Innovation Foundation | Lipid-surfactant nanoparticles for drug delivery and methods of making and uses thereof |
US11788190B2 (en) | 2019-07-05 | 2023-10-17 | Asm Ip Holding B.V. | Liquid vaporizer |
US11788091B2 (en) | 2019-08-21 | 2023-10-17 | University Of Virginia Patent Foundation | Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
US11946136B2 (en) | 2019-09-20 | 2024-04-02 | Asm Ip Holding B.V. | Semiconductor processing device |
WO2021076794A1 (en) | 2019-10-15 | 2021-04-22 | Cornell University | Methods for modulating level of expression from gene therapy expression cassette |
AU2020367437A1 (en) | 2019-10-16 | 2022-06-02 | Cornell University | Gene therapy for Alzheimer's disease |
US20230001017A1 (en) | 2019-10-28 | 2023-01-05 | University Of Lowa Research Foundation | Formulation for delivery of lubricin gene |
KR20220107243A (ko) | 2019-11-25 | 2022-08-02 | 코넬 유니버시티 | Apoe 유전자 요법 |
IL297486A (en) | 2020-04-23 | 2022-12-01 | Univ Iowa Res Found | gper-targeted chimeras of protein degradation |
US20230293678A1 (en) | 2020-08-21 | 2023-09-21 | Aliasger K. Salem | Cationic nanoparticle adjuvants |
WO2022047201A1 (en) | 2020-08-27 | 2022-03-03 | University Of Iowa Research Foundation | Gene knock-out for treatment of glaucoma |
CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
CA3201219A1 (en) | 2020-12-04 | 2022-06-09 | Mir Ali | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
WO2022125963A1 (en) | 2020-12-11 | 2022-06-16 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
EP4340894A1 (de) | 2021-05-21 | 2024-03-27 | University Of Iowa Research Foundation | Antioxidationsmittelhaltige partikel und verfahren zur verwendung |
CN113332442A (zh) * | 2021-06-10 | 2021-09-03 | 愈美明德(成都)生物医药科技有限公司 | 一种靶向递送分子、粒子及其制备方法、应用 |
WO2022271951A1 (en) | 2021-06-23 | 2022-12-29 | University Of Iowa Research Foundation | Sustained release formulations comprising a selective androgen receptor modulator |
CN113785975B (zh) * | 2021-09-09 | 2023-08-29 | 天津医科大学 | 精胺、亚精胺脂质体在抗氧化、抗衰老中的应用 |
WO2023057935A1 (en) * | 2021-10-06 | 2023-04-13 | Seqirus Inc. | Lipid nanoparticle comprising a nucleic acid-binding protein |
WO2023240156A1 (en) | 2022-06-08 | 2023-12-14 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU599456B2 (en) * | 1986-11-28 | 1990-07-19 | Liposome Company, Inc., The | Phospholipid composition |
US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
CA2271325A1 (en) * | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
-
1998
- 1998-05-12 US US09/076,618 patent/US6210707B1/en not_active Expired - Lifetime
-
1999
- 1999-05-11 DE DE69937450T patent/DE69937450T2/de not_active Expired - Lifetime
- 1999-05-11 EP EP99922950A patent/EP1078079B1/de not_active Expired - Lifetime
- 1999-05-11 CA CA2330741A patent/CA2330741C/en not_active Expired - Lifetime
- 1999-05-11 AU AU39834/99A patent/AU770111B2/en not_active Expired
- 1999-05-11 ES ES99922950T patent/ES2296391T3/es not_active Expired - Lifetime
- 1999-05-11 AT AT99922950T patent/ATE377082T1/de not_active IP Right Cessation
- 1999-05-11 JP JP2000548485A patent/JP4427186B2/ja not_active Expired - Lifetime
- 1999-05-11 EP EP06008157A patent/EP1724353A3/de not_active Withdrawn
- 1999-05-11 WO PCT/US1999/010375 patent/WO1999058694A1/en active IP Right Grant
-
2001
- 2001-01-16 US US09/765,107 patent/US6528087B2/en not_active Expired - Lifetime
-
2002
- 2002-06-21 US US10/177,939 patent/US6803053B2/en not_active Expired - Lifetime
-
2004
- 2004-05-17 US US10/847,982 patent/US7022336B2/en not_active Expired - Lifetime
-
2006
- 2006-02-27 US US11/363,986 patent/US20060147513A1/en not_active Abandoned
-
2009
- 2009-09-30 JP JP2009226639A patent/JP2010031028A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20030003143A1 (en) | 2003-01-02 |
EP1078079A1 (de) | 2001-02-28 |
US6803053B2 (en) | 2004-10-12 |
JP4427186B2 (ja) | 2010-03-03 |
US20020001612A1 (en) | 2002-01-03 |
US20060147513A1 (en) | 2006-07-06 |
AU770111B2 (en) | 2004-02-12 |
US20040209366A1 (en) | 2004-10-21 |
EP1724353A3 (de) | 2007-04-04 |
US6210707B1 (en) | 2001-04-03 |
ES2296391T3 (es) | 2008-04-16 |
EP1078079A4 (de) | 2002-03-13 |
EP1078079B1 (de) | 2007-10-31 |
DE69937450T2 (de) | 2008-08-21 |
EP1724353A2 (de) | 2006-11-22 |
WO1999058694A1 (en) | 1999-11-18 |
DE69937450D1 (de) | 2007-12-13 |
US7022336B2 (en) | 2006-04-04 |
CA2330741C (en) | 2013-08-13 |
US6528087B2 (en) | 2003-03-04 |
JP2010031028A (ja) | 2010-02-12 |
AU3983499A (en) | 1999-11-29 |
CA2330741A1 (en) | 1999-11-18 |
JP2002514432A (ja) | 2002-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE377082T1 (de) | Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damit | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
PT983087E (pt) | Composicao de vacina multivalente com veiculo misto | |
WO2007012013A3 (en) | Polymer conjugates to therapeutic agents via an si-n and/or an si-o linkage | |
BR0010721A (pt) | Composições de neisserias combinadas | |
AU2001250882A1 (en) | Inorganic particle conjugates | |
DE69714654D1 (de) | Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen | |
ATE376026T1 (de) | Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren | |
TR200002050T2 (tr) | Selüloza bağlanabilen polisakkarit konjugesi. | |
ATE541587T1 (de) | Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen | |
DK1200479T3 (da) | Multiple cytokin-antistof-komplekser | |
ATE319483T1 (de) | Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren | |
DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
ATE505233T1 (de) | Elektromagnetische felder zur therapie von krebs und dergleichen | |
CA2312202A1 (fr) | Composition cosmetique capillaire sous forme d'emulsion eau-dans-silicone comprenant au moins un polymere fixant | |
DE69822473D1 (de) | Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen | |
DE69932733D1 (de) | Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene | |
DE60216305D1 (de) | Zusammensetzungen zur verabreichung von arzneimittelkombinationen | |
ATE221595T1 (de) | Verfahren zur herstellung von papier, pappe und karton | |
BR9811839A (pt) | Plasma sanguìneo universalmente aplicável | |
EP2260843A3 (de) | Alpha-MSH und Derivate zur Induktion von Antigentoleranz | |
DK1220852T3 (da) | Substituerede diazepaner | |
BR0014371A (pt) | Misturas de polìmeros contendo poliésteres modificados | |
DE29713859U1 (de) | Vorrichtung zur Herstellung von Saucen, Teigen o.dgl. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |